Experienced in Hypogonadism Primary Partial Alopecia

Dr. Osvaldo F. Padron

Urology
Florida Urology Partners Llp
12408 N 56th St, Suite 1, 
Temple Terrace, FL 
Accepting New Patients
Experienced in Hypogonadism Primary Partial Alopecia
Florida Urology Partners Llp
12408 N 56th St, Suite 1, 
Temple Terrace, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Osvaldo Padron is an Urologist in Temple Terrace, Florida. Dr. Padron is rated as an Experienced provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Frequent or Urgent Urination, Urinary Incontinence, Enlarged Prostate (BPH), Ureteroscopy, and Sacral Nerve Stimulation. Dr. Padron is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Specialist in FL
Hospital Affiliations
Florida Hospital Carrollwood
Tampa General Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

FLORIDA UROLOGY PARTNERS LLP
12408 N 56th St, Suite 1, Temple Terrace, FL 33617
Other Locations
FLORIDA UROLOGY PARTNERS LLP
5913 Webb Rd, Tampa, FL 33615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Axonics SacRal NeuromodulaTIon System RegisTRY Study : ARTISTRY
Axonics SacRal NeuromodulaTIon System RegisTRY Study : ARTISTRY
Enrollment Status: Completed
Publish Date: September 22, 2025
A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
Stage 2B of: A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer
Stage 2B of: A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 01, 2023
Intervention Type: Device
Study Phase: Not Applicable
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer
A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

9 Total Publications

Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence.
Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence.
Journal: The Journal of urology
Published: November 25, 2024
Similar Doctors
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Lonnie T. Klein
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Lonnie T. Klein
Urology

Advanced Urology Institute LLC

1840 Mease Dr, Suite 300, 
Safety Harbor, FL 
 (19.1 miles away)
727-785-6011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lonnie Klein is an Urologist in Safety Harbor, Florida. Dr. Klein is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Urinary Tract Infection in Children, Enlarged Prostate (BPH), Urinary Tract Infection (UTI), Ureteroscopy, and Prostatectomy. Dr. Klein is currently accepting new patients.

Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Denis E. Healey
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. Denis E. Healey
Urology

Advanced Urology Institute LLC

609 W Highland Blvd, 
Inverness, FL 
 (53.4 miles away)
352-726-9707
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Denis Healey is an Urologist in Inverness, Florida. Dr. Healey is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Enlarged Prostate (BPH), Ureteroscopy, and Prostatectomy. Dr. Healey is currently accepting new patients.

Distinguished in Hypogonadism Primary Partial Alopecia
Dr. James M. Zachary
Urology
Distinguished in Hypogonadism Primary Partial Alopecia
Dr. James M. Zachary
Urology
1840 Mease Drive, Suite 300, 
Safety Harbor, FL 
 (19.1 miles away)
727-785-6011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Zachary is an Urologist in Safety Harbor, Florida. Dr. Zachary is rated as a Distinguished provider by MediFind in the treatment of Hypogonadism Primary Partial Alopecia. His top areas of expertise are Urinary Tract Infection in Children, Enlarged Prostate (BPH), Eunuchoidism Familial Hypogonadotropic, Prostatectomy, and Ureteroscopy. Dr. Zachary is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Padron's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile